New study aims to predict fracture risk in bone cancer patients
NCT ID NCT06524843
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
Researchers are gathering medical records, scans, and lab results from 250 patients with bone metastases that spread from other cancers. They will use this data to create a dataset called RAW, which will help develop computer models to predict fracture risk and life expectancy. The study does not test any new drug or treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better tools for doctors to predict fracture risk and life expectancy in patients with bone metastases.
- What could go wrong
- This is an observational study that only collects existing data, so it won't directly test a new treatment. The models may not work as hoped in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Male and female adult patients, affected by bone metastases derived from carcinoma, treated at Rizzoli Ortopaedic institute from 01/01/2010 to 31/12/2022.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of bone metastasis from carcinoma, regardless of the type of carcinoma, and of the number and location of the metastases * Availability of imaging and clinical data * Availability of at least one follow-up during the last 12 months form diagnosis Exclusion Criteria: * At least one inclusion creteria not met
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bone metastases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
IRCCS Istituto Ortopedico Rizzoli
RECRUITINGBologna, Emilia-Romagna, 40134, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can radiation boost a personalized prostate cancer vaccine?
- Preventive radiation may stop bone events before they start — a trial puts it to the test
- Can a new capsule ease bone metastasis pain without opioids?
- Hip muscle repair method may improve walking after bone cancer surgery
- New model aims to predict jaw bone disease before it strikes
- Could removing the primary tumor boost survival in stage IV breast cancer with Bone-Only spread?